Abstract. Gammacarboxyglutamate (Gla) is an uncommon amino acid formed by vitamin K action. Increasing evidence indicates that Gla-proteins are involved in the regulation of calcification processes in both bone tissue and atherosclerotic vessel wall. In a population-based study we have previously shown that in a group of 113 postmenopausal women the presence of abdominal aortic calcifications is associated with a reduced vitamin K status. In the present study we investigated whether this reduced vitamin K status was also associated with differences in bone mass or circulating calciotropic hormone levels. Serum immunoreactive osteocalcin with low affinity for hydroxyapatite (irOC free ) was used as a marker for vitamin K status. After correction for age it was found that women with atherosclerotic calcifications had a 7% lower bone mass as measured by metacarpal radiogrammetry (mean difference: 3.2 mm 2 , 95% CI: −0.2-6.5, P ‫ס‬ 0.06). No differences between both groups of women were observed for serum intact parathyroid hormone (PTH) and serum 25-hydroxyvitamin D levels. In the atherosclerotic women (n ‫ס‬ 34), markers for vitamin K status were inversely associated with bone mass (r ‫ס‬ −0.47, P ‫ס‬ 0.013), whereas no such association was found in the nonatherosclerotic women (n ‫ס‬ 79). It is concluded that the atherosclerotic women in this study may be at higher risk for osteoporotic fractures as evidenced by their lower bone mass and higher serum irOC free levels. The finding that in atherosclerotic women vitamin K status is associated with bone mass supports our hypothesis that vitamin K status affects the mineralization processes in both bone and in atherosclerotic plaques.
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Osteoporosis and atherosclerosis are two major chronic causes of morbidity. Although they tend to be regarded as two independent, age-related processes, it is striking that in women the prevalence of both disorders increases dramatically after menopause [1] . Estrogen deficiency or a derangement in calcium metabolism have been proposed as candidates for common pathophysiological factors [2] [3] [4] .
Results from recent studies suggest that atherosclerotic calcification must be regarded as a highly regulated process similar to that occurring in bone tissue [5] . It is of interest that in both calcification processes vitamin K-dependent proteins are thought to be involved [6] [7] [8] [9] . Vitamin Kdependent proteins have calcium-binding properties mediated by the posttranslationally acquired ␥-carboxyglutamate (Gla) residues [10] . A diminished availability of vitamin K, e.g., due to a reduced nutritional intake or impaired intestinal absorption, may result in a decreased Gla-content of the various Gla-proteins. In the latter case, Gla-proteins, such as osteocalcin, will be functionally defective resulting in a reduced affinity for the hydroxyapatite bone matrix. This can be measured in serum as the serum immunoreactive osteocalcin with a low affinity for hydroxyapatite (irOC free ) [11] . The high affinity osteocalcin (irOC bound ), expressed as a percentage of total serum osteocalcin, is called the hydroxyapatite-binding capacity of osteocalcin (HBC) and is regarded as a measure for osteocalcin Glacontent and for vitamin K status [12] [13] [14] . Since the correlation between circulating vitamin K and tissue vitamin K is unclear at this time, undercarboxylated Gla-proteins form a unique tool to assess the vitamin K status in the tissues from which these proteins originate. It has been suggested that even a mild vitamin K deficiency may affect calcium homeostasis. In a number of trials, we have recently shown that markers of bone formation increase, whereas bone resorption markers decrease with the administration of pharmacological doses of vitamin K [12] [13] [14] . These data are consistent with two Japanese studies, both of which demonstrated that vitamin K supplementation may retard postmenopausal loss of bone mass [15, 16] . We have recently shown that in a group of postmenopausal women, the presence of atherosclerotic calcifications in the abdominal aorta, considered to be a strong predictor of cardiovascular heart disease and mortality [17] [18] [19] , is associated with a marginal vitamin K status [20] . In the present study we examined whether the reduced vitamin K status in the atherosclerotic women was associated with a reduced bone mass as well.
Materials and Methods

Subjects
Participants were selected from a population-based study on determinants of osteoporosis and atherosclerosis [21] . Bone mass Correspondence to: C. Vermeer Calcif Tissue Int (1996) 59:352-356 measurements as well as the extent of calcified deposits in the abdominal aorta were determined in 1985. In 1990, 256 women consented to take part in a follow-up examination [20] . In brief, aortic calcification (grade 3 or grade 4) was found to be present in 34 subjects. Seventy-nine women without aortic calcification (grade 0) were randomly selected from the cohort. Subjects using vitamin K antagonists were excluded.
Abdominal Aorta Calcification
Atherosclerosis of the abdominal aorta was assessed using a lateral X-ray film of the lumbar spine (T12-S1), from which the presence of calcified deposits was determined [22] . The severity of the atherosclerosis was graded from 0 (no calcifications) to 4 (aorta outlined with calcifications) [20] .
Bone Mass
Bone mass measurements was determined using metacarpal radiogrammetry. The outer diameter (D) and medullar diameter (d) were measured at the midshaft of the metacarpal bones, using a 7 times magnifying measurement loop with an accuracy of 0.01 mm. Bone mass (metacarpal cortical area) was expressed as the mean
) of the metacarpal bones II, III, and IV of both hands. The mean intra-individual standard deviation (SD) of a duplicate measurement was 1.9 mm 2 (4%), which is in accordance with previous reports [23] .
Anthropometric Variables
Height and weight were measured without shoes and with indoor clothing. The body mass index (kg/m 2 , BMI) was calculated. The circumferences of the waist and hip were measured and the waistto-hip ratio (WH-ratio) was calculated.
Vitamin K Status
Immediately after preparation, the nonfasting serum and plasma samples were frozen at −80°C. Serum immunoreactive osteocalcin (irOC) levels were measured before (irOC total ) and after (irOC free ) extraction with 100 mg/ml hydroxyapatite [12] . Serum irOC bound was calculated from the difference between irOC total and irOC free . The HBC was calculated as the percentage of irOC bound relative to the total serum irOC level and used as an overall estimate of the Gla-content of circulating irOC levels. In young, healthy adults, the HBC values range between 70 and 80%; decreased values are found in subjects with a marginal vitamin K status [12, 13] . Interand intraassay coefficients of variation of serum irOC total were 10% and 5%, respectively.
Additional Measurements
Serum intact parathyroid hormone levels (iPTH) were measured with a direct immunoradiometric assay (IRMA) (N-tact) PTH SP) and serum 25-hydroxyvitamin D (250HD) levels were determined using radioimmunoassay (RIA) (both obtained from Incstar, Stillwater, MI).
Data Analysis
Multiple linear regression was used for analysis of differences across groups with and without atherosclerosis, adjusted for confounding variables such as age. The differences are presented with a 95% confidence interval (95% CI). Analyses were performed using the BMDP statistical package. Results are presented as the mean values (± SD) unless indicated otherwise.
Results
As reported previously, no major differences were noted between the women with or without atherosclerosis with respect to their age (67.8 ± 5.5 and 66.1 ± 4.1, respectively), BMI 25.4 ± 3.2 and 26.5 ± 3.0 kg/m 2 , respectively), or WH-ratio (0.84 ± 0.05 and 0.84 ± 0.06, respectively) [20] . The atherosclerotic women had higher serum total cholesterol levels (7.56 ± 1.05 mmol/liter) compared with the nonatherosclerotic women (6.85 ± 1.00 mmol/liter, P < 0.01), whereas no difference was noted in their serum HDLcholesterol levels (1.84 ± 0.65 and 1.74 ± 0.94 mmol/liter, respectively).
The bone mass of the atherosclerotic and nonatherosclerotic women was 41.6 and 45.1 mm 2 , respectively, constituting a mean difference of 3.5 mm 2 (95% CI: −6.7, −0.2) or 8% (P ‫ס‬ 0.04) ( Table 1) . Adjustment for age slightly attenuated the difference to −3.2 mm 2 (95% CI: −6.5, 0.2 P ‫ס‬ 0.06). In the atherosclerotic women, bone mass was significantly associated with both serum irOC free (r ‫ס‬ −0.47, P ‫ס‬ 0.013) and HBC levels (r ‫ס‬ 0.57, P ‫ס‬ 0.002) ( Table 2 ). No such associations were found in the women without atherosclerosis (Table 2) . Adjustment for age, BMI, or serum cholesterol did not essentially alter these findings (data not shown).
No differences were observed in serum iPTH and 250HD levels (Table 1) . Serum 250HD levels of 12 ng/liter (considered as borderline value) and lower were present in 44% of the women [24, 25] . In both the atherosclerotic and nonatherosclerotic women, bone mass was positively associated with serum 250HD levels (pooled data: r ‫ס‬ 0.23, P ‫ס‬ 0.07), but not with serum iPTH (pooled data: r ‫ס‬ 0.10, P ‫ס‬ 0.36) ( Table 2 ). Serum iPTH levels were significantly associated with serum irOC free (pooled data: r ‫ס‬ 0.30, P ‫ס‬ 0.002) and HBC (pooled data: r ‫ס‬ −0.27, P ‫ס‬ 0.005) levels in both groups. The associations remained essentially unchanged after additional adjustments for possible confounders as age, BMI, and serum cholesterol levels.
Discussion
The results of our study indicate that in postmenopausal women the presence of atherosclerotic calcifications in the abdominal aorta is not only associated with a marginal vitamin K status [20] , but also with a low bone mass. In comparisons of necropsy with computed tomography findings, atherosclerotic calcifications in the abdominal aorta have previously been shown to represent severe aortic atherosclerosis [26, 27] . These calcifications have shown to be strong predictors of coronary heart disease [28, 29] and cardiovascular mortality [18, 19, 28] . Assessment of bone mass by radiogrammetry based on multiple measurements of six metacarpal bones, on the other hand, has been shown to be sufficiently precise for meaningful comparisons of bone density between individuals [21, 23] . Low bone mass is a well established and important risk factor for the development of osteoporotic fractures [30, 31] . Recent data strongly indicate that high serum irOC free levels are associated with an increased risk for hip fractures [32] and that in elderly women, elevated serum irOC free levels are associated with a low bone mass [33] . The findings of our study that atherosclerotic women had a low bone mass and high irOC free levels therefore strongly suggest that they are at increased risk for developing osteoporotic fractures.
Several studies have reported that both low bone mass and increased frequency of osteoporotic fractures are associated with atherosclerotic calcifications [2, 3, [34] [35] [36] [37] or cardiovascular deaths [4, 38] . Some have regarded the observed associations merely as being age-related phenomena [35, 36] , whereas others have suggested a causal relationship [2, 3, 34, 38] . High serum levels of iPTH or 250HD have been proposed as causally related factors, however, this is not supported by our data. The 250HD and iPTH serum levels in our study are in accordance with other studies performed in The Netherlands [24, 25] . The relatively high serum iPTH levels in our study population are indicative of a secondary hyperparathyroidism commonly found in women of this age [25, 39] . The finding that serum iPTH is associated with serum irOC free levels suggests that serum irOC free may result from PTH-mediated bone resorption [40] . Although it is assumed that serum irOC free consists of undercarboxylated osteocalcin, there is some evidence that at least part of the circulating irOC free is formed by denatured osteocalcin or osteocalcin degradation products, possibly originating from bone resorption [14, 40] .
Accumulating evidence suggests that vitamin K stimulates bone formation and inhibits bone resorption which ultimately may lead to a decrease in bone loss [12] [13] [14] [15] [16] . The fact that only in the atherosclerotic women both markers for vitamin K status were strongly associated with bone mass suggests that additional (as yet unknown) factors may be of importance. It has been suggested for instance that abnormalities in lipoprotein metabolisms may influence vitamin K transport to bone tissue [41] .
The question remains What may be the pathophysiological mechanism in which a reduced vitamin K status leads to a lower bone and an increased frequency of atherosclerotic calcifications. Recent evidence strongly supports the concept that the calcification associated with atherosclerosis must be regarded as an active, highly organized process similar to that of osteogenesis [5, 42] . Gla-proteins appear to be involved in both processes [6, 8, 9] . The Gla-proteins MGP (matrix Gla-protein) and osteocalcin are both involved in the bone mineralization process. Their exact function, however, is still unclear. Recently, high levels of MGP mRNA and protein were demonstrated in macrophages and in vascular smooth muscle cells, present in human atherosclerotic plaques [9] . This strongly suggests that MGP found in the plaques is not absorbed from the blood stream, but that it is produced locally at the site of these plaques. We speculate that the function of vascular MGP is similar to that in bone [43] , i.e., that it acts as a mineralization inhibitor. By analogy with the fetal warfarin syndrome [44] , undercarboxylation of MGP would thus be a risk factor for excessive mineralization of the atherosclerotic vessel wall. Osteocalcin, on the other hand, is predominantly synthesized by the more differentiated osteoblast, relatively late in bone development, concomitant with or after the onset of mineralization [45] . Also, its different molecular properties and tight association with the mineral matrix suggest a different function for osteocalcin, for instance, in bone remodeling or in the accumulation of bone mass [46] . In mature bone tissue, a suboptimal vitamin K status might thus affect the osteocalcin-mediated remodeling process ultimately leading to a net loss of bone mass [12] [13] [14] [15] [16] .
In conclusion, we found that the presence of atherosclerotic calcifications in postmenopausal women is associated Table 1 ; where correlations were ommitted, no significance was observed with an impaired vitamin K status as well as a low bone mass. These findings support the view that aortic calcification and bone loss may be two related processes, with vitamin K deficiency as a common denominator. Further studies are needed to investigate the potential benefit of vitamin K supplementation.
